197 related articles for article (PubMed ID: 9388058)
1. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
[TBL] [Abstract][Full Text] [Related]
2. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
5. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
[TBL] [Abstract][Full Text] [Related]
6. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
Aryandono T; Harijadi ; Ghozali A
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
[TBL] [Abstract][Full Text] [Related]
7. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
8. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
9. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
11. The classification of ductal carcinoma in situ and its association with biological markers.
Bobrow LG; Happerfield LC; Gregory WM; Springall RD; Millis RR
Semin Diagn Pathol; 1994 Aug; 11(3):199-207. PubMed ID: 7831531
[TBL] [Abstract][Full Text] [Related]
12. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome.
Joshi MG; Lee AK; Loda M; Camus MG; Pedersen C; Heatley GJ; Hughes KS
Cancer; 1996 Feb; 77(3):490-8. PubMed ID: 8630956
[TBL] [Abstract][Full Text] [Related]
13. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
14. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
16. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
Arafah M
Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers.
Bobrow LG; Happerfield LC; Gregory WM; Millis RR
J Pathol; 1995 Aug; 176(4):333-41. PubMed ID: 7562248
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
19. [Male breast cancer. Histochemical and flow cytometry analysis of 6 cases].
Galasso MG; Galia A; Gazzano G; Cosentino A; Castorina S
Pathologica; 1995 Oct; 87(5):503-5. PubMed ID: 8868175
[TBL] [Abstract][Full Text] [Related]
20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
